Profile data is unavailable for this security.
About the company
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
- Revenue in USD (TTM)2.00bn
- Net income in USD-332.08m
- Incorporated2003
- Employees2.10k
- LocationAlnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
- Phone+1 (617) 551-8200
- Fax+1 (617) 551-8101
- Websitehttps://www.alnylam.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medpace Holdings Inc | 1.96bn | 312.32m | 11.97bn | 5.80k | 39.37 | 17.78 | 35.22 | 6.10 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
BIO-TECHNE Corp | 1.15bn | 202.97m | 12.16bn | 3.05k | 61.38 | 6.04 | 38.79 | 10.54 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
United Therapeutics Corporation | 2.50bn | 1.05bn | 12.20bn | 1.17k | 13.02 | 2.28 | 11.04 | 4.88 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.27bn | 1.31k | 1,629.97 | 12.77 | 208.99 | 8.75 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Viatris Inc | 15.36bn | -56.10m | 12.62bn | 38.00k | -- | 0.6305 | 4.77 | 0.8216 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Incyte Corp | 3.77bn | 745.44m | 12.98bn | 2.52k | 17.55 | 2.41 | 15.62 | 3.44 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Natera Inc | 1.21bn | -365.46m | 13.08bn | 3.28k | -- | 16.40 | -- | 10.82 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 13.63bn | 1.45k | 37.21 | 5.71 | 34.75 | 6.88 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.25bn | 3.40k | 71.06 | 2.81 | 45.87 | 5.77 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 18.78bn | 2.10k | -- | -- | -- | 9.37 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 12.79m | 10.11% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 11.70m | 9.26% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.43m | 7.46% |
Wellington Management Co. LLPas of 31 Mar 2024 | 7.21m | 5.70% |
Baillie Gifford & Co.as of 31 Mar 2024 | 6.62m | 5.24% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.11m | 4.84% |
Dodge & Coxas of 31 Mar 2024 | 3.81m | 3.01% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 3.65m | 2.89% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.59m | 2.84% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.19m | 2.52% |